Choriocarcinoma (Gestational Trophoblastic Neoplasia) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Choriocarcinoma (Gestational Trophoblastic Neoplasia) – Drugs In Development, 2024 report and make more profitable business decisions.
Gestational trophoblastic disease (GTD) is a group of rare tumors that develop during the early stages of pregnancy. Most GTD tumors are benign (noncancerous), but some may turn into malignant (cancerous). GTD is categorized into hydatidiform moles and gestational trophoblastic neoplasia (GTN). Risk factors include age younger than 20 or older than 35, previous molar pregnancy, and history of miscarriage. Symptoms include bleeding or discharge not related to menstruation, larger than usual uterus in pregnancy, and pain or mass in the pelvic area. It can be diagnosed through internal pelvic examination, pap test, transvaginal ultrasound, and urinalysis. Methods of treatment include surgery, chemotherapy, hysterectomy, and radiation therapy.
The Choriocarcinoma (Gestational Trophoblastic Neoplasia) drugs in development market research report provide comprehensive information on the therapeutics under development for Choriocarcinoma (Gestational Trophoblastic Neoplasia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Choriocarcinoma (Gestational Trophoblastic Neoplasia) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Choriocarcinoma (Gestational Trophoblastic Neoplasia) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Choriocarcinoma (Gestational Trophoblastic Neoplasia) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Choriocarcinoma (Gestational Trophoblastic Neoplasia) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Choriocarcinoma (Gestational Trophoblastic Neoplasia) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Table of Contents
Table
Figures
Frequently asked questions